TD Cowen initiated coverage of Sionna Therapeutics (SION) with a Buy rating. Sionna’s pipeline of cystic fibrosis therapies directly target ...

Goldman Sachs initiated coverage of Sionna Therapeutics (SION) with an Early-Stage Biotech designation. Lead assets SION-719 and SION-451 are ...

U.S.-based companies are dragging down the major stock market indexes. But getting caught up in short-term market movements ...

Vertex Pharmaceuticals Incorporated ( NASDAQ: VRTX) TD Cowen 45th Annual Health Care Conference Transcript March 3, 2025 3:10 PM ET David Altshuler - Executive Vice President, Global Research and CSO ...

After an illustrious career, including 12 years as director of the NIH and leading the HGP consortium, Francis Collins announces his sudden resignation.

Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...

The committee supports approving the CFTR modulator for patients 2 years and older with at least one non-class I CFTR gene mutation.

Boston, USA-based biotech Sionna Therapeutics has recently raised $191 million through its initial public offering (IPO), marking a step forward in its efforts to develop treatments for cystic ...

AbbVie, Danaher, Organovo, Thermo Fisher Scientific, and Vertex Pharmaceuticals are the five Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of ...

The amAIz Suite now leveraging Google Cloud capabilities will further accelerate generative AI adoption in the telecom ...